Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

Tsimafeyeu, Ilya; Zolotareva, Tatiana; Варламов, Сергей; Зуков, Р. А.; Петкау, В. В.; Mazhbich, Mikhail; Statsenko, Galina; Safina, Sufia; Zaitsev, Igor; Сакаева, Д. Д.; Popov, Alexander; Borisov, Pavel; Vladimirova, Liubov

doi:10.1016/j.clgc.2017.07.017

Cited by 26 publications

(19 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[26][27][28][29] We also present the treatment reality of recent years, whereas existing literature has often covered a shorter observation period than ours. 26,28,30,31 Over time, our data show a decline of sunitinib treatment in favor of pazopanib, following European marketing approval. The British RECCORD (Renal Cell Carcinoma Outcomes Research Dataset) registry also reported a shift from sunitinib to pazopanib between 2009 and 2012, with sunitinib remaining the most common first-line treatment.…”

Section: Discussionmentioning

confidence: 76%

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry

Goebell

Staehler

Müller³

et al. 2018

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

This is the first prospective long-term cohort study showing changes in treatment reality and survival of routine patients with clear cell mRCC. Newly approved treatments are quickly applied in routine care. Patients with unfavorable prognosis, including trial-ineligible patients, have inferior outcomes. Survival times of potentially trial-eligible patients are similar to those reported from clinical trials.

show abstract

Section: Discussionmentioning

confidence: 76%

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry

Goebell

Staehler

Müller³

et al. 2018

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

show abstract

“…Наиболее распространенным вариантом рака почки является светлоклеточный ПКР [7], ассоциированный с высокой частотой инактивирующих мутаций гена фон Гиппеля-Линдау, приводящих к гиперэкспрессии HIF и HIF-зависимых сигнальных путей, прежде всего VEGF / VEGFR, FGF / FGFR и PDGF / PDGFR [8]. HIF-зависимые ростовые факторы и их рецепторы принимают участие в регуляции опухолевого ангиогенеза, митогенеза, а также формировании опухолевого микроокружения и являются основными мишенями тар гетной терапии ПКР [9][10][11][12].…”

Section: Discussionunclassified

Expression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma

et al. 2020

View full text Add to dashboard Cite

Objective: to assess the expression and prognostic value of vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2) and their receptors VEGFR-1, -2; FGFR-1, -2, as well as platelet-derived growth factor receptors (PDGFR-α, PDGFR-β) in paired samples of primary tumors and tumor thrombi in renal cell carcinoma (RCC).Materials and methods. Expression of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β was studied in paired surgical samples of primary tumors and tumor thrombi in 25 patients with clear cell RCC pT3a–T4N0–1M0–1 and tumor venous thrombosis by immunohistochemical assay using the appropriate Abcam/Santa Cruz Biotech antibodies from the immunohistochemical staining kit Invitrogen. Expression levels were evaluated by a semi-quantitative method (H-score). The analysis of the correlation between expression levels of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β and RCC characteristics, as well as evaluation of their influence on the outcome of RCC were performed.Results. VEGF-A, FGF-2, as well as VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β were expressed in the cytoplasm and on the membrane of the primary tumor and tumor thrombus cells in RCC patients. Tumor thrombus cells were characterized by lower expression of VEGFR-1, VEGFR-2, PDGFR-α (p <0.05 for all) and tendency to lower expression of VEGF-A (p = 0.060), FGF-2 (p = 0.046), FGFR-1 (p = 0.077) and FGFR-2 (p = 0.090) compared with primary tumor cells. RCC Furman grade correlated with the expression levels of VEGFR-1 (p = 0.035) and FGFR-1 (p = 0.022) in the primary tumor cells, tumor invasion into venous wall correlated with the expression levels of VEGFR-1 (p = 0.023) and FGFR-2 (p = 0.005) on the thrombus cells. VEGFR-2 overexpression in the primary tumor cells was associated with significant decrease of overall survival (OS) rate (p = 0.011). There was a tendency to OS deterioration in cases with overexpression of VEGFR-2 (p = 0.093) and VEGF-A (p = 0.095) in the tumor thrombus cells. One-year OS in patients with ³2 identified risk factors was 27.3 %, <2 risk factors – 87.5 % (p = 0.004).Conclusion. Tumor thrombus cells in RCC patients expressed VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β less active than the cells of the primary tumor. Overexpression of growth factors and tyrosine kinases correlated with RCC Furman grade and tumor venous wall invasion. Overexpression of VEGFR-2 in both primary tumor and thrombus cells in combination with hypoexpression of VEGF-A in the thrombus negatively influenced on OS.

show abstract

“…Согласно результатам ретроспективного регистро-вого исследования RENSUR5 в период с 2010 по 2011 г. таргетную терапию 1-й линии в России проводили 13,4 % больных мПКР [9][10][11]. Во 2-й линии лекарст-венное лечение было назначено 15,7 % пациентов, а таргетная терапия -10,5 %.…”

Section: Discussionunclassified

Five-year overall survival of metastatic renal cell carcinoma patients treated with everolimus after progression on bevacizumab: a prospective multicenter study CRAD001LRU02T

Safina¹,

Варламов²,

Снеговой³

et al. 2018

Cancer Urology

View full text Add to dashboard Cite

show abstract

Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

Cited by 26 publications

References 3 publications

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry

Expression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma

Five-year overall survival of metastatic renal cell carcinoma patients treated with everolimus after progression on bevacizumab: a prospective multicenter study CRAD001LRU02T

Contact Info

Product

Resources

About